墨西哥三个地区HIV治疗前耐药趋势研究
该研究纵向评估了2008至2016年墨西哥三个地理区域(中央都市区、坎昆和蒂华纳)HIV感染者的治疗前耐药(PDR)。2012-16年PDR分别为13.4%、8.9%和11.2%,NNRTI耐药最高;三个地区依非韦伦耐药均呈上升趋势,主要与K103N频率增加相关。研究提示应进行地方性耐药监测并采取本地化干预。
要点
- 2012-16年PDR在中央都市区、蒂华纳和坎昆分别为13.4%、8.9%和11.2%。
- NNRTI耐药在三个地区最高,分别为8.7%、4.8%和8.1%(P<0.05)。
- 2008-16年三个地区依非韦伦耐药均上升,2016年分别达11.8%、6.1%和8.3%。
核心结论
- 墨西哥三个地理区域NNRTI治疗前耐药患病率和传播动态存在差异。
- 尽管三个地区依非韦伦耐药均呈上升趋势,但观察结果支持在墨西哥这样的大国进行地方性监测和本地化干预。
研究设计与样本
- 纵向评估HIV治疗前耐药,招募2008至2016年未接受抗逆转录病毒治疗的HIV感染者。
- 样本来自中央都市区(n=1194)、坎昆(n=773)和蒂华纳(n=668)。
- 使用Stanford HIVdb工具从血浆HIV pol序列估计治疗前耐药。
主要发现
- 蒂华纳女性比例更高、教育程度和就业率更低,中央都市区MSM比例更高(所有比较P<0.0001)。
- 2012-16年PDR在中央都市区、蒂华纳和坎昆分别为13.4%、8.9%和11.2%。
- NNRTI PDR在三个地区最高,分别为8.7%、4.8%和8.1%(P<0.05);蒂华纳NNRTI PDR低于中央都市区(P=0.01)。
- 2008-16年三个地区依非韦伦耐药均呈上升趋势(所有P<0.05),2016年分别达11.8%、6.1%和8.3%。
- 依非韦伦耐药增加主要与K103N频率增加相关(中央都市区P=0.007,蒂华纳P=0.03,坎昆无统计学意义)。
关键数值与推荐
- 2012-16年PDR:中央都市区13.4%,蒂华纳8.9%,坎昆11.2%。
- NNRTI PDR:中央都市区8.7%,蒂华纳4.8%,坎昆8.1%(P<0.05)。
- 2016年依非韦伦耐药:中央都市区11.8%,蒂华纳6.1%,坎昆8.3%。
临床怎么用
- 在墨西哥等大国应开展地方性HIV耐药监测,以指导本地化干预。
- 考虑地区间NNRTI耐药差异,治疗前耐药检测和方案选择可能需要结合地区流行病学数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pretreatment drug resistance (PDR) levels to NNRTI approaching 10% have recently been reported in Mexico. However, subnational differences may exist in PDR prevalence and transmission dynamics. OBJECTIVES: We longitudinally assessed HIV PDR in three geographic areas of Mexico. PATIENTS AND METHODS: HIV-infected, antiretroviral-naive individuals were recruited from 2008 to 2016, from the Central Metropolitan Zone (CMZ), Cancun and Tijuana (1194, 773 and 668 respectively). PDR was estimated using the Stanford HIVdb tool from plasma HIV pol sequences. RESULTS: A higher proportion of females, lower education and lower employment rate were observed in Tijuana, while a higher proportion of MSM was observed in the CMZ (P < 0.0001, all cases). For 2012-16, PDR was 13.4%, 8.9% and 11.2% in the CMZ, Tijuana and Cancun respectively. NNRTI PDR was highest in the three regions (8.7%, 4.8% and 8.1% respectively, P < 0.05); nevertheless, NNRTI PDR in Tijuana was lower than in the CMZ (P = 0.01). For 2008-16, we observed increasing efavirenz resistance trends in all regions (P < 0.05, all cases), reaching 11.8%, 6.1% and 8.3% respectively in 2016. Increasing efavirenz resistance was mostly associated with increasing K103N frequency (P = 0.007 CMZ, P = 0.03 Tijuana, not significant for Cancun). CONCLUSIONS: Our study suggests different NNRTI PDR prevalence and transmission dynamics in three geographical areas of Mexico. Even when increasing trends in efavirenz resistance were observed in the three areas, our observations support that, in a large country such as Mexico, subnational surveillance and locally tailored interventions to address drug resistance may be a reasonable option.
引用
- García-Morales C, Tapia-Trejo D, Quiroz-Morales VS, et al. HIV pretreatment drug resistance trends in three geographic areas of Mexico. J Antimicrob Chemother. 2017. PMID: 28961972. doi:10.1093/jac/dkx281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。